INCY241220C75000
- 0.01
- -0.24-96.00%
Incyte Newsroom
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Incyte Price Target Raised to $70 From $68 at Wells Fargo
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Incyte Analyst Ratings
UBS Initiates Incyte(INCY.US) With Hold Rating, Announces Target Price $77
Express News | Incyte : UBS Initiates Coverage With Neutral Rating; Target Price $77
Incyte to Present at Upcoming Investor Conference
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Incyte's Mixed Clinical Results and Financial Challenges Lead to Hold Rating
Express News | Incyte : Leerink Partners Raises Target Price to $100 From $87
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $82
Incyte (NASDAQ:INCY) Shareholders Have Lost 22% Over 5 Years, Earnings Decline Likely the Culprit
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $52
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
Incyte's Growth Prospects Hampered by Pipeline Setbacks and Market Challenges
Positive Outlook on Incyte's Stock: InMIND Study Validates Tafasitamab Combination Efficacy and Safety